Clinical trials: Gout and Hyperuricemia

Gout and Hyperuricemia

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

• Completed
• Age: 20 to 70 years
• Phase 2
• Results posted

This study is to examine the hypothesis that administration of RDEA3170 to Japanese patients with gout or asymptomatic hyperuricemia in doses of 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg once daily, respectively will result in…

Trial name

NCT02078219

Testing

RDEA3170, Allopurinol

Where

14 sites in Japan

Volunteers

204 people

Sponsor

AstraZeneca